Kailera Therapeutics Secures Major Funding
Kailera Therapeutics has raised $600 million in a Series B financing to support the advancement of its lead obesity drug, KAI-9531, into Phase III clinical development. The round follows the company’s $400 million Series A completed last year, marking a rapid rise for the biotechnology firm, which emerged from stealth in 2024 with exclusive ex-China rights to several obesity-focused candidates.
Details of the Financing
Bain Capital led the latest financing, continuing its backing of Kailera’s expansion. The investor’s life sciences division co-led Kailera’s initial $400 million Series A, while Bain’s private equity arm headed the new round. Kailera stated that the Series B will be fully funded at closing, allowing the company to conduct large-scale trials typically undertaken by major pharmaceutical companies.
Phase III Program for KAI-9531
The new investment is among the largest private biotech financings this year, matching the $600 million round secured by AI-driven drug discovery firm Isomorphic Labs in March. Kailera said the funds will primarily be used to launch a global Phase III program for its injectable dual GLP-1/GIP receptor agonist, KAI-9531. The company has completed end-of-Phase II meetings with the U.S. Food and Drug Administration and plans to begin late-stage testing by the end of the year.
The upcoming Phase III program will include three studies: one in adults with a body mass index of 35 kg/m² or higher, and two in adults with overweight or obesity with comorbidities—one with and one without Type 2 diabetes.
Promising Efficacy Data
KAI-9531, which was originally discovered and developed by Jiangsu Hengrui Pharmaceuticals, has shown significant weight-loss potential in earlier studies. In a Phase III trial conducted in China by Hengrui, the treatment achieved a placebo-adjusted weight loss of 16.3% after 48 weeks, with the top dose continuing to show improvement through the end of the study. In a separate report, Kailera and Hengrui noted that participants lost an average of 17.7% of body weight at 48 weeks, with 88% of treated patients reducing their weight by at least 5% and 44.4% achieving a loss of at least 20%.
Commenting on the company’s progress, a Kailera spokesperson said, “The financing will support the advancement of our lead program into global Phase III development.”
Expanding the Obesity Portfolio
Beyond KAI-9531, the Series B proceeds will also fund Kailera’s broader obesity portfolio. This includes KAI-7535, an oral GLP-1 receptor agonist expected to enter global studies following favorable Phase II results in China, and KAI-4729, a GLP-1/GIP/glucagon receptor tri-agonist designed to address metabolic disease. Kailera also plans to develop a once-daily oral version of KAI-9531.
Strategic Partnership and Investors
The company’s pipeline stems from its partnership with Jiangsu Hengrui, which licensed the three obesity-focused assets to Kailera in 2024. The collaboration also grants Kailera rights to new formulations of licensed drugs and first-refusal options on selected Hengrui metabolic disease programs.
The Series B round was led by Bain Capital Private Equity and joined by Royalty Pharma, Adage Capital Management, and a large mutual fund that was not disclosed by name.
Competitive Landscape
Kailera’s new funding comes amid heightened activity in the obesity drug market. Recent transactions include Pfizer’s $4.9 billion acquisition of Metsera, Roche’s $1.65 billion collaboration with Zealand Pharma, and major investments from Eli Lilly and Novo Nordisk in new obesity partnerships.
With the fresh capital, Kailera plans to initiate its global Phase III trials for KAI-9531 this year and continue advancing its growing metabolic disease pipeline.
Kailera’s bold Series B raise also positions it to invest in real-world evidence generation and downstream market access strategies. The company aims to collect longitudinal patient data to validate durability of effect, safety in broader populations, and comparative effectiveness versus existing GLP therapies.
Moreover, the firm is exploring combination strategies — pairing KAI-9531 with agents targeting appetite regulation or energy expenditure — to maximize therapeutic response in difficult-to-treat obesity subsets. Kailera may also leverage digital health tools to improve adherence and patient engagement, which is critical in chronic obesity management.
